MTATP6P15

Across TCGA pan-cancer cohorts, MTATP6P15 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated MTATP6P15 data layer.

The strongest signal is observed in testicular germ cell tumors (TGCT), where higher MTATP6P15 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTATP6P15 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

TGCT, LIHC, and STAD are the cancer types where MTATP6P15 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
TGCT	OS	Tertile	III,IV	0.003	1.000	<.001	72	view →
LIHC	OS	Tertile	All	0.089	0.786	<.001	45	view →
STAD	DFS	Tertile	III,IV	0.367	0.536	.011	26	view →
PAAD	DFS	Tertile	All	0.185	0.411	.012	18	view →
LUAD	DFS	Tertile	All	0.946	0.795	.015	12	view →
HNSC	DFS	Tertile	IV	1.000	0.408	.029	9	view →
KIRC	OS	Quartile	All	0.505	0.659	.021	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MTATP6P15–TGCT (OS)

Open the TGCT breakdown →